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With improvements in treatment for childhood cancer, comparisons of survival rates between countries have become important to
inform future health policies and treatment strategies. Population-based cancer registry data are viewed as the gold standard for such
comparisons, but even these have potential confounding factors. Here, we review the interpretation of recent geographical
comparisons of childhood cancer survival from the viewpoint of the British Isles, a region with a 45-year record of national
population-based cancer registration and a national childhood cancer clinical trials organisation in place for nearly 30 years. Using
national data on referral patterns to tertiary paediatric oncology centres, we explore some of the reasons for lower survival rates in
the past for some tumour groups and anticipate continued improvement in the next decade. Participation in international clinical trials
coincided with rapid gains in survival for hepatoblastoma. This exemplifies the potential benefits of international collaborative clinical
research, particularly for rare subgroups.
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Successful treatment of childhood cancer relies on many factors,
some of which are inherent to each tumour’s biology but some of
which can be more readily influenced, such as early recognition
of concerning symptoms by families and physicians, referral
practices and the availability and implementation of optimal,
usually standardised, treatment protocols. Survival from childhood
cancer in the UK has been the subject of international comparisons
since the EUROCARE studies in the 1990s (Coebergh et al, 2001;
Terracini et al, 2001). Most recently, interregional comparisons of
both incidence and survival across Europe have been made using
the Automated Childhood Cancer Information System (ACCIS)
(Steliarova-Foucher et al, 2004). In this study, the regions were
defined largely according to UN definitions. As the UK and
Republic of Ireland have national population-based cancer
registration and contributed large numbers of cases, their data
were analysed and presented as a single group under the heading
of ‘British Isles’ (BI), separately from the North European region
(Pritchard-Jones et al, 2006). This allows comparisons of the basic
demographics and outcome for childhood cancer treatment in the
BI to be made with other European regions. Although such
comparisons may be useful in assessing the effectiveness of cancer
services for children, they also raise questions for those subgroups
where outcomes are significantly different from the European
average. We consider here possible reasons for these differences,
particularly whether they are more likely to be attributable to
differences in disease occurrence or patterns of care or to be
artefacts arising from variations in cancer registry practice across
Europe. In the ACCIS analyses, the most recent year of diagnosis
for most of the BI was 1995 (Steliarova-Foucher et al, 2006), but
the results are also discussed in the context of trends in survival in
Great Britain up to 2000 and rates of referral to paediatric oncology
centres up to 2002.
Before drawing any conclusions from these analyses, one must
take into consideration the comparability of the data sources.
Comparability issues were considered carefully in deciding which
registry data should be included in the ACCIS analyses. Cancer
registration is a complex process that relies on comprehensive
access to hospital and population records, however, and compar-
ability is not yet perfect owing to national variations in registration
practices and access to personal data (Pritchard-Jones et al, 2006;
Steliarova-Foucher et al, 2006). For example, incidence and
survival figures in registries without access to national mortality
databases (as in Germany, France, Netherlands, Italy and Spain)
may overestimate survival owing to incomplete follow-up for vital
status (Steliarova-Foucher et al, 2006). The data for the BI suffer
less from this, as legislation permits linkage to databases of
identifiable deceased individuals. The ACCIS analyses refer to all
diagnoses in the International Classification of Childhood Cancer
(Kramarova and Stiller, 1996), that is, all malignant neoplasms and
most types of non-malignant intracranial and intraspinal tumours.
Although the latter are collected routinely by most cancer
registries, there are some variations between registries and hence
also between geographical regions, whose implications for inter-
pretation of the results are discussed below.
In the most recent period of the ACCIS analysis (1988–1997),
observed overall 5-year survival for 49651 children aged under 15
years grouped into the five European regions was 72% (Sankila
et al, 2006). Observed survival was used in place of relative
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www.bjcancer.comsurvival, as competing causes of death are rare in children in
Western populations and relative survival would exceed observed
survival by less than one percentage point. For comparison, the 5-
year relative survival was 75% in the USA for patients diagnosed in
1985–1999 (Ries et al, 2003). Observed survival ranged from 77%
in the North, through 75% in the West, 72% in the South, 71% in
the BI to 62% in the East (Sankila et al, 2006). The survival curves
tested by log rank were significantly different for the BI compared
individually with North, West or East, but were not distinguishable
from survival in the South. For this analysis, the regions included
data from the following countries: North (Denmark, Iceland,
Finland, Norway), West (France, Germany (East and West 1991–
1997; former West Germany only 1988–1990), Netherlands,
Switzerland), South (Italy, Malta, Slovenia, Spain), BI (Ireland,
England, Northern Ireland, Scotland, Wales) and East (Belarus,
Estonia, Hungary, Slovakia). Trends in survival were analysed over
the 20-year period 1978–1997 with some slight differences in the
regional data sets: BI (England, Scotland and Wales), East (Estonia,
Hungary, Slovakia, former East Germany, 1978–1987), South
(Italy, Slovenia, Spain) (Magnani et al, 2006) (Figure 1). The
relative ranking of regions did not alter over this longer study
period. Highly significant increases in observed survival were seen
in all European regions, with the most rapid rise in the East. For all
neoplasms, the BI had a 5-year survival of 74% in the most recent
period, 1993–97 (Magnani et al, 2006). Survival has continued to
increase, reaching 77% in Great Britain (which accounts for about
90% of cases in the BI) during 1996–2000 (Figure 2) (Stiller, 2007).
The reported survival differences between the BI and some other
European regions are small in absolute terms. Some of this
variation may be artefactual due to several possible factors. First,
it should be noted that the BI had the lowest incidence rates in
Europe for all childhood cancers combined. The age-standardised
rate was 131.1 per million compared with 138.5 per million for
Europe as a whole with the highest rate of 160.1 per million in the
North (Stiller et al, 2006a). The deficit was found among boys and
girls at all ages throughout childhood. It was most marked in the
first year of life, with more than half of the difference from the
European average being accounted for by the relatively low
incidence of neuroblastoma among infants (Stiller et al, 2006a).
Incidence rates may influence survival in several ways. For
example, survival will increase if there is ‘overdiagnosis’ of cases
with a very favourable prognosis that may not otherwise
have presented clinically, as has been observed for neuroblastoma
(Spix et al, 2006). Variations in diagnostic and registration
practices for brain tumours may contribute to higher survival in
those regions covered by registries with a higher total incidence
resulting from inclusion of a higher proportion of non-malignant
cases (Peris-Bonet et al, 2006).
The significance of comparisons of survival among North,
South, West and BI for the 12 main groups and the principal
subgroups of childhood cancers is weakened by their ‘post hoc’
nature and the fact that the large number of comparisons means
that some significant results would be expected to arise by chance.
In general, the highest survival figures were often observed in the
North. Differences were seen between the BI and the region(s) with
highest 5-year survival for sympathetic nervous system tumours,
renal tumours and soft tissue sarcomas (Pastore et al, 2006a,b;
Spix et al, 2006). Differences in observed survival were also noted
for the following subgroups: neuroblastoma, Wilms tumour, acute
lymphoblastic leukaemia (ALL), osteosarcoma, primitive neuro-
ectodermal tumours/medulloblastoma and ‘glioma-related’ brain
tumours, although the composition of this last subgroup is too
heterogeneous for meaningful comparison, as explained below
(Coebergh et al, 2006; Peris-Bonet et al, 2006; Pastore et al, 2006a;
Spix et al, 2006; Stiller et al, 2006b). Despite these limitations,
possible reasons for these potential differences in certain tumour
groups merit further consideration, as they may be informative in
stimulating assessment of factors with the potential to influence
effectiveness of care.
For neuroblastoma, it has been recognised previously that the
BI has a lower total incidence that includes a relatively high
proportion of older children with disseminated disease, compared
with some other Western European countries (Powell et al, 1998).
This pattern of presentation may be partially explained by the
influence of screening programmes and differences in the use
of diagnostic ultrasound in paediatric primary care in other
European countries and may, to some extent, explain the lower
survival in Great Britain during 1988–1995. Survival has improved
consistently since this period (Figure 3). This improvement is not
easily explained as the same clinical trial for the major subgroup of
children with stage 4 disease (ENSG V, 1990–1999) ran throughout
both periods. Further analysis would require data that are beyond
the current scope of cancer registries, such as participation rates in
randomised clinical trials, where the more intensive experimental
arm subsequently showed a survival benefit.
Survival for children with renal tumours in the BI, comprising
mainly Wilms tumours, remained static in the BI during the ACCIS
study period and was similar to rates in the South, but inferior to
rates in the North and West (Pastore et al, 2006a). This overall
picture suggesting no change is confounded by an unexplained fall
in survival in the early 1990s compared with the late 1980s (Stiller,
2007). Overall survival has subsequently improved markedly,
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Figure 1 Five-year actuarial cumulative survival for all childhood cancers,
by European region and period of diagnosis (source: Magnani et al, 2006)
Trends in survival after childhood cancer in Europe, 1978–1997: the
ACCIS project. Eur J Cancer 42:1981–2005). For details of the countries
included in each of the regions, see main text. Reproduced with the
permission of the European Journal of Cancer.
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Figure 2 Actuarial 5-year cumulative survival for all childhood cancers
diagnosed in Great Britain (England, Wales, Scotland) during the period
1971–2000. Source: Stiller C (2007) Childhood Cancer in Britain: Incidence,
Survival and Mortality, Oxford University Press: Oxford, UK.
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national strategy for treatment of relapsed Wilms tumour in the
late 1990s (Figure 3).
Geographical comparisons of survival from soft tissue sarcomas
are complicated by the fact that this diagnostic group encompasses
a diverse collection of histological entities with widely differing
prognosis, together with the possibility that terminology and
registration practice varied systematically between regions. Most
notably, the North had the highest incidence and survival rates for
the subgroup of fibrosarcoma and allied tumours, and the
possibility that this was attributable to inclusion of some cases
of non-malignant conditions such as fibromatosis could not be
excluded (Pastore et al, 2006b). The subgroup of ‘Other specified
soft tissue sarcomas’, for which the North and South regions had
markedly higher survival rates than the BI and West, is also very
heterogeneous and includes tumour types with widely differing
survival. The difference in survival between the BI and the North
was twice as large for all soft tissue sarcomas combined, as it was
for rhabdomyosarcoma, the most well-defined and least hetero-
geneous subgroup in European children. The differences between
the BI and South (which had the highest survival of any European
region for rhabdomyosarcoma) were similar for rhabdomyo-
sarcoma and for all soft tissue sarcomas. In both ACCIS and
EUROCARE 3, interregional variation in survival from STS
diminished between the 1970s and 1990s (Gatta et al, 2005;
Coebergh et al, 2006; Pastore et al, 2006b; Stiller et al, 2006b).
For all leukaemias combined, there was no significant difference
between any of the four non-East regions of Europe. However,
observed survival for ALL was statistically better in the North and
West regions than in BI and South (Coebergh et al, 2006). There
was no significant difference in outcome for acute non-lympho-
blastic leukaemia between the same regions. As organisation of
specialist care for children with leukaemia in the UK is similar
regardless of subtype, this suggests that differences in treatment
rather than other aspects of care underlie the survival difference.
Indeed, as treatment protocols for ALL were changed in the late
1990s to introduce more sustained intensification blocks, overall
survival has continued to increase, with 3-year overall survival
having reached over 90% in the most recent quinquennium (Vora
et al, 2006; Stiller, 2007).
For children with osteosarcoma, survival was lower in the BI
than in the North, West and South (Stiller et al, 2006b). There was
no such interregional difference in observed survival for Ewing’s
sarcoma. A contributing factor may have been different ap-
proaches to treatment of osteosarcoma during the period studied
by ACCIS. Over the entire period covered by the ACCIS survival
comparisons (1988–1997), the standard chemotherapy for osteo-
sarcoma in the BI was the two drug combination of cisplatin and
doxorubicin, whereas the majority of the other European sarcoma
study groups were using multidrug combinations including high
dose methotrexate (Souhami et al, 1997; Fuchs et al, 1998).
Although the European Osteosarcoma Intergroup (EOI) rando-
mised studies did not show significant benefit for any of the
multidrug combinations tested against the two drug combination,
their EFS was at the lower end of the international range. A three
drug combination has now been accepted as the standard for the
current joint European–American osteosarcoma trial in which the
EOI participates (EURAMOS 1; www.euramos.org).
The category of central nervous system tumours presents the
most challenges for data comparisons, due to national variation
in coding, registration of non-malignant tumours and the low
proportion of tumours with a microscopically verified diagnosis.
For the category ‘other gliomas’, 58% were diagnosed only
clinically with large interregional variation (Peris-Bonet et al,
2006). There was a high level of interregional variation in the
relative frequencies of cases in the subgroups IIIa (ependymoma,
including choroid plexus tumours), IIIb (astrocytoma) and IIId
(other glioma), resulting at least in part from differences in
diagnostic and classification criteria. Most notably, the ratio of
age-standardised incidence rates for astrocytoma to other glioma,
which was 3.8:1 overall, ranged for individual regions from 1.2:1
in the North (influenced by there being no separate code for
‘astrocytoma’ in Finland) to 5.5:1 in the East. As discussed earlier,
this heterogeneity does not permit meaningful comparisons. In an
attempt to overcome this problem, survival rates were analysed for
a category of ‘glioma-related’ tumours, which combined these
three subgroups. Even for this combined category, however, there
was considerable interregional variation in recorded incidence.
The North had an especially high overall incidence rate of 26.0
per million, probably reflecting higher rates of diagnosis and
registration for low-grade tumours, whereas incidence rates were
lower in the West when compared with the BI as the reference
region. These differences may explain the better survival of all
brain tumours in the North compared with the other three regions,
BI, South and West.
Survival within the diagnostic subgroups varied according to
the geographical region of residence. Children with PNET had
lower survival in the BI or East than in the other three regions.
Classification and coding of PNET may be assumed to be fairly
consistent internationally. Therefore, it is likely that at least some
of this survival difference is due to treatment approaches. For
example, a substantial proportion of children with non-metastatic
medulloblastoma were treated with radiotherapy alone during the
1990s, in contrast to the greater use of adjuvant chemotherapy in
other European countries (Taylor et al, 2003). Children with brain
tumours have lagged behind other groups of childhood cancers in
accessing multidisciplinary specialised care. During the ACCIS
study period, only two-thirds of children diagnosed with a brain
tumour in Great Britain were referred to a UKCCSG centre
(Table 1). This has subsequently increased to 85% in the period
1996–2000 and has coincided with a continued improvement in
survival (Figure 3).
DISCUSSION AND CONCLUSIONS
We have described the potential confounding factors in perform-
ing survival comparisons across Europe. We have taken the
example of the BI comparisons to explore possible reasons for
such differences. The reported survival differences are small in
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Figure 3 Actuarial 5-year cumulative survival for specified childhood
cancers diagnosed in Great Britain during the period 1971–2000. Source:
Stiller C (2007) Childhood Cancer in Britain: Incidence, Survival and Mortality,
Oxford University Press: Oxford, UK.
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tumour types. However, the consistency of the findings regarding
the relative ranking of the BI in comparison with the Nordic
countries and the West, contributed mainly by the former West
Germany in both the Eurocare and ACCIS analyses, requires
further examination. It is incumbent on clinical investigators to
take note of trends and identify areas for improvement. If we
accept that survival levels seen in the Nordic countries represent
those that the BI could reasonably aspire to at the current time, we
need to consider the factors that could theoretically lead to an
improvement in survival. Access to specialist care for children with
cancer has been well established through the Children’s Cancer
and Leukaemia Group (CCLG, formerly UK Children’s Cancer
Study Group (UKCCSG) since the mid-1980s. By the early 2000s,
90% of children with the major childhood cancers were being
referred to CCLG centres (Table 1).
The data on neuroblastoma suggest that for some diagnostic
categories, it is possible that children are diagnosed at a later stage
than their northern European or German counterparts. This may
reflect differences in patterns of primary care and child health
checks for the young age group in which embryonal tumours
typically present. The National Institute for Health and Clinical
Excellence (NICE) referral guidelines for suspected cancer,
published in June 2005 and applicable in England and Wales,
include specific guidance on when to suspect cancer in children
(NICE, 2005a). These should improve urgent referral to secondary
paediatric services for more timely investigation.
Treatment must be considered as a possible contributing factor
to the observed survival differences. Referral to a specialist centre
and treatment within a clinical trial are generally viewed as ‘best
practice’ for all childhood cancers and there is evidence that
treatment within a clinical trial is associated with better survival
(Stiller and Eatock, 1999). This approach is endorsed in the
recently published NICE guidance document: ‘Improving Out-
comes in Children and Young People with Cancer’ (NICE, 2005b).
This document also emphasises the importance of multidisciplin-
ary team working to implement the complex diagnostic and
therapeutic requirements for effective cancer treatment in this age
group.
In the period covered by the ACCIS comparisons (1988–1997),
81% of all children with cancer in the BI were referred to a CCLG
(UKCCSG) centre. The majority were enrolled in a relevant
national clinical trial. Central nervous system tumours were the
main category where the proportion of children referred for
specialist oncology care was low and for which there were very few
open clinical trials. By the early 2000s, the referral rate had
improved to 85% and there is now a comprehensive portfolio of
clinical trials for childhood brain tumours. Since the early 1990s,
there has been an increasing trend for the CCLG (UKCCSG) to
participate in international collaborative clinical trials, initially in
solid tumours and more recently in leukaemias. The success of
international collaboration in clinical trials is exemplified by the
dramatic improvement in survival for hepatoblastoma from 37%
in the era before the opening of the first SIOPEL trial in 1990 to
70% in the next quinquennium (Figure 3). The improvement in
survival for all cancers and for the tumour subgroups where the BI
differed from the best regions in Europe continues into the most
recent period for which mature 5-year survival data are available
and shows no signs of levelling off (Figures 2 and 3). In England
and Wales, implementation of the NICE guidance means that
multidisciplinary teams have been strengthened in many centres.
Similar guidance is being implemented in Scotland. These changes
in service delivery and increasing international collaboration are
expected to have a continued positive effect on outcome. It is
therefore essential that systems remain in place to permit ongoing
geographical comparisons of incidence of and survival from
childhood cancer. Clinical investigators and cancer registries
should also pursue ways to collect more detailed information to
permit analysis of hypotheses as to why overall survival rates
continue to increase even during time periods when the same
clinical trial protocols are running. Such information should
include disease free not just overall survival together with
participation rates in randomised clinical trials. Such analyses
provide an important basis for countries to examine the impact of
their national strategies to develop services for children with
cancer.
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